About

Enabling physicians to make personalized treatment recommendations for cancer patients

Avant Diagnostics, Inc. (formerly known as Theranostics Health, Inc.) is a medical diagnostic technology company focused on commercializing innovative biomarker technologies that have the potential to dramatically improve treatment outcomes in the areas of oncology and neurology. The Company's lead technology, called Theralink(r), was developed to empower cancer treating physicians with actionable information make time sensitive treatment decisions for their patients. Theralink was designed to inform physicans which treatments are likely to be effective for their patients at any given moment in time, and also identify which treamtents are unlikely to be effective. This information has the potential to improve treatment efficacy and reduce side effects by foregoing ineffective therapy.

Cancer tumor biomarker profiling: Driving innovation in personalized medicine

At Avant Diagnostics, our approach is based on more than 10 years of research and development that informs our philosophy the genetic information alone is insufficient to make patient specific treatment recommendations. Our phospho-proteomic approach, which focuses on measuring the quantity and intensity of drug target activation in the tumor tissue following standard biopsy procedures, exploits our understanding of drug-receptor interaction that is the driver of treatment response . Our advanced technology is being developed to reduce the prescription of ineffective, toxic treatments and guide physicians towards therapies that are most likely to lead to positive responses to treatment. Our large panel of markers targeted at already-approved FDA drugs, as well as certain investigational therapies, makes Theralink an invaluable tool for oncologists.

Market opportunity: Cancer biomarkers market expected to reach $33B by 2025

According to Grand View Research, the market for cancer biomarkers is expected to grow from $10.3B in 2016 to $33.7B by 2025, representing a compound annual growth rate (CAGR) of 14.6%. The market is currently comprised primarily of genetic biomarkers that have good predictive value on a population basis, but limited value on an individual patient basis. Proteomic markers represent a growing segment of the cancer biomarker market, and offer the promise to improve individual patient outcomes based upon the individual patient's tumor proteomic profile.

Within the proteomic cancer biomarker category, phosphoprotein analysis represents a uniquely positioned asset class that can more robustly predict treatment outcomes based upon the molecular mechanisms driving tumor growth and treatment resistance. As such, the Company believes it has the potential to be the market leader in this phospho-proteomic subcategory.

Science Backed by Strong Leadership

Meet the team that is the driving force behind our success.

View Management Team »